Condensyl and Procrelia can be taken by every men and women, even without diagnostic tests
Being based on the principle of the indirect antioxidant activity Condensyl and Procrelia will not cause, by definition, metabolic perturbations. Thus, they do not carry particular limitations of use and can be taken by everybody without fixed duration limits: the benefits to metabolism and cellular physiology will last as long as the supplementation remains in place.
Nevertheless, those assuming the dietary support due to specific needs, i.e. seeking procreation, should take the products under the guide of a specialist and with the aid of diagnostic investigations that will allow to check whether the support does produce the targeted outcomes and whether there are any adjustments to implement.
Several tests that can be of guidance in the use of Condensyl e Procrelia are mentioned Here below whereas it is better to refer to a specialised physician for a comprehensive panorama of the available diagnostic options.
Condensyl (and less specifically also Procrelia) exerts its action primary by sustaining the recycling of homocysteine, which is a recognised risk factor for cardiovascular diseases, neurodegenerations, cancers and others.
The test for circulating plasma homocysteine is available at every lab and is commonly offered as part of the standard blood biochemistry . Subjects with high homocysteine may use Condensyl among the tools for the correction of such risk factor. However, a normal blood homocysteine does not exclude the potential usefulness of Condensyl.
Subjects integrating their diet with Condensyl often record an improvement of their blood lipids and it may be worth to control such aspects to check the effects of the treatment. To do so, the main tests, besides homocysteine, are the dosage of cholesterol and tryglicerides and the rate of HDL cholesterol.
In particular cases, e.g. known metabolic diseases or investigation of specific risk factors, it may be useful to undergo genetic tests to detect the presence of a low activity genetic variant of any of the key enzymes of metabolism, see below. These tests are always to be executed under the guidance of a qualified expert.
Men seeking paternity should always perform an analysis of the sperm in the hands of an experienced urologist. A normospermic framework does not exclude the utility of the treatment with Condensyl ™ as damage from oxidative stress are not normally visible in this examination. In contrast, subjects with oligospermia (low sperm count), teratospermia (abnormal forms) and asthenospermia (reduced motility) are more likely to suffer from a contemporary oxidative stress and are particularly suitable for the treatment.
Men with known fertility problems or belonging to couples with long lasting infertility and/or resistant to ART practices and/or with a history of repeated miscarriages should undergo more specific tests for the detection of sperm oxidative damage. The measurement of the DNA fragmentation index (DFI) is offered by many laboratories, although with varying methods. High DFI is an elective indication to treatment with Condensyl™. Treatment should be continued until a significant reduction in the DFI occurs. Clinical studies indicate that a reduction of 10% of DFI (eg. From 35% to 25%) is sufficient to improve the reproductive prognosis.
The measurement of the Sperm DNA Fragmentation Index (SDI), simple and inexpensive, is so far offered only by few laboratoties. However, it is known that men carrying a SDI hogher than 30% do not have any chances to conceive by natural routes.
Condensyl™ is the first and so far only available treatment that was able to reduce the SDI within controlled clinical studies.
A pathologic increase of the SDI may be caused by the assumption of strong antioxidants e configures a net worsening of the reproductive prognosis . Subjects assuming such treatments should control their SDI after the treatment and consider a cycle with Condensyl™ if the value is increased.
Females in fertile age should always undergo, together with other tests, an ultrasound investigation of the pelvis. Besides providing useful information on the ongoing ovulatory process, ultrasound testing may show the presence of a polycistic ovary. Such findings may associate to hyperandrogenism/hirsutism, hyperinsulinemia, ovulatory disturbances and infertility. Treatment with Condensyl™ may contribute to improve these symptoms, to nurmalise ovulation and to increase the chances of pregnancy.
In some cases ultrasounds may demonstrate the presence of endometriosis, i.e. an abnormal extrauterine occurrence of endometrial mucosa, which is as well a possible cause of infertility. Also in these cases treatment with Condensyl™ may improve the symptoms and the chances of pregnancy.
Couples with a history of infertility, especially if resistant to ART practices or with modest embryo development in vitro, lack of implant and recurrent miscarriage should consider further investigations.
Here, the test with the highest prognostic impact is Pre-implantation Genetic Screening (PGS). The test is intended to count the number of chromosomes in the cells for the presence of aneuploidy, i.e. the presence of chromosomes in excess or in defect, which is generally incompatible with a term development of the fetus. This test can be done either on the spermatozoa (average in the ejaculate) or on oocytes (polar bodies surrogate testing). However, it is most commonly used on embryos at the blastocyst stage so to choose the normal ones for subsequent transfer into the uterus. The occurrence of aneuploidy in the gametes, and consequently in embryos derived from such gametes, is in part linked to oxidative stress. A supporting cycle with Condensyl ™ may result in a larger rate of euploid embryos among those available for transfer.
Another test that is advisable to couples resistant to ART practices is the search for pathologic (less active) genetic variants of the key enzymes of metabolism, which are in fact very frequent. The most commonly tested genes are named MTHFR, the enzyme that activates folic acid, and MTRR, the enzyme that activates vitamin B12. Both the enzymes are involved in the cycle of the carbon, further endorsing the central role of such metabolic pathways in the reproductive function. A possible remedy for the subjects carrying these pathologic variants is a nutritional support intended to compensate the reduced activity of the enzyme with an excess of its substrate. Condensyl is duly formulated to provide such substrates and is the product of choice. However, the carriers of defects that are more serious (e.g. homozygous) and/or combined (more than one defect at the same time) may be resistant also Carriers of these conditions are invited to contact us to get the due guidance.